Phospholipid Ether Synthesis via Organozinc Cross-Coupling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The synthesis of phospholipid ether analogs for cancer therapy is currently a multi-step process that requires hazardous reagents and lacks versatility in terms of starting reactants, particularly in alkyl chain length, making it time-consuming and dangerous.
Innovation Solution
A method involving the cross-coupling of organo zinc reagents with alkyl halides using Ni(II)-Pybox or Pd-PEPPSI catalysts, allowing for the synthesis of phospholipid ether analogs with varying alkyl chain lengths at room temperature or below, without the use of Grignard reactions, thereby improving safety and versatility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If Grignard reactions are used in the synthesis of phospholipid ether analogs, then the synthesis can be performed, but hazardous reagents are required and safety risks increase
Solution Approach 1:
The patent uses organozinc reagents as intermediaries in place of highly reactive Grignard reagents. The organozinc reagents are less hazardous and can be handled more safely, yet still enable the cross-coupling reaction with alkyl halides to form phospholipid ether analogs. This substitution of the intermediary substance resolves the contradiction between synthesis feasibility and safety.
2Ease of manufacture
If traditional multi-step synthesis procedures are used for phospholipid ether analogs, then the synthesis can be completed, but the process is time-consuming and lacks versatility in alkyl chain length
Solution Approach 1:
The patent employs transition metal catalysts (Ni(II)-Pybox or Pd-PEPPSI) that enable the synthesis to proceed under milder conditions and with greater efficiency. The catalytic system allows for variation in alkyl chain length parameters without requiring complete redesign of the synthesis pathway, thus reducing time loss while maintaining synthesis completion.
Solution Approach 2:
The cross-coupling methodology developed in the patent is universally applicable to synthesizing phospholipid ether analogs with different alkyl chain lengths. The same reaction protocol and catalyst system can accommodate various starting materials, making the process versatile and reducing the need for multiple specialized procedures.
3Ease of manufacture
If traditional synthesis methods are used, then phospholipid ether analogs can be synthesized, but versatility in starting reactants and alkyl chain length is limited
Solution Approach 1:
The patent develops a universal cross-coupling platform that can accept various organozinc reagents and alkyl halides as starting materials. This multi-functional approach allows synthesis of phospholipid ether analogs with diverse alkyl chain lengths and structures, greatly enhancing reactant versatility while maintaining synthesis capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the efficient synthesis of high specific activity phospholipid ether analogs for cancer treatment, including primary, secondary, and metastatic cancers, with enhanced safety and versatility in reactant usage, as demonstrated by effective tumor targeting and treatment outcomes.
Implementation Method 1
A method involving the cross-coupling of organo zinc reagents with alkyl halides using Ni(II)-Pybox or Pd-PEPPSI catalysts
Data Source
AI summary
Disclosed are improved methods for the synthesis of phospholipid ether analogs and alkyl phosphocholine analogs. The methods allow greater versatility of the reactants used and greater ease in synthesizing alkyl chains of varying length while affording reaction temperatures at room temperature or below. The methods disclosed herein provide reactants and conditions using alkyl halides and organozinc reagents and do not utilize Gringard reactions thus, allowing greater ease of their separation and purity of products. The PLE compounds synthesized by the methods disclosed herein can also be used for synthesizing high specific activity phospholipid ether (PLE) analogs, for use in treatment and diagnosis of cancer.